Document Detail

Recommendation recall and satisfaction after attending breast/ovarian cancer risk counseling.
MedLine Citation:
PMID:  17674165     Owner:  NLM     Status:  MEDLINE    
This study examined women's recall of physician recommendations as well as patient satisfaction following participation in a breast/ovarian cancer risk and prevention program. Participants were 41 high risk women who attended a cancer risk program 4-6 months earlier. Two-thirds of women who received recommendations for tamoxifen treatment and genetic testing did not recall these recommendations upon follow-up. A number of women misunderstood recommendations and a quarter of the sample recalled recommendations that were not made during the consultation. Although these high risk women were generally satisfied with their counseling visit, those individuals who received particularly complex sets of recommendations reported feeling less understood and were less satisfied with the counseling. Findings underline the importance of examining recommendation recall, in addition to perceptions of cancer risk, when evaluating the clinical implications of cancer risk assessment.
Sharon L Bober; Lizbeth A Hoke; Rosemary B Duda; Nadine M Tung
Related Documents :
19744825 - Decreased accuracy in interpretation of community-based screening mammography for women...
2909185 - Differences in the timeliness of diagnosis, breast and cervical cancer, san francisco 1...
18755565 - Women's perceptions of their treatment decision-making about breast cancer treatment.
17131315 - Body size, hormone therapy and risk of breast cancer in asian-american women.
18983115 - "life without line dancing and the other activities would be too dreadful to imagine": ...
22409635 - Psychosocial factors in adolescent nicotine dependence symptoms: a sample of high schoo...
Publication Detail:
Type:  Journal Article     Date:  2007-08-04
Journal Detail:
Title:  Journal of genetic counseling     Volume:  16     ISSN:  1059-7700     ISO Abbreviation:  J Genet Couns     Publication Date:  2007 Dec 
Date Detail:
Created Date:  2007-11-08     Completed Date:  2008-03-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9206865     Medline TA:  J Genet Couns     Country:  United States    
Other Details:
Languages:  eng     Pagination:  755-62     Citation Subset:  IM    
Department of Pediatric Oncology (SLB), Dana-Farber Cancer Institute, Dana 321, 44 Binney Street, Boston, MA 02215, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents, Hormonal / therapeutic use
Breast Neoplasms / drug therapy,  epidemiology*,  genetics,  psychology
Genetic Counseling*
Hospitals, Teaching
Ovarian Neoplasms / epidemiology*,  genetics,  psychology
Patient Satisfaction*
Tamoxifen / therapeutic use
Reg. No./Substance:
0/Antineoplastic Agents, Hormonal; 10540-29-1/Tamoxifen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Novel, monomeric cyanine dyes as reporters for DNA helicase activity.
Next Document:  Career research interests and training of genetic counseling students.